MDS Nordion of Ottawa has entered into an agreement with a Russian company to develop, market, and sell molybdenum-99 (Mo-99) radioisotopes produced in Russia.
Called Isotope, the company is the authorized subsidiary of Rosatom State Corporation of Moscow, the regulatory body of the Russian nuclear complex. The 10-year collaboration between MDS Nordion and Isotope may result in the creation of joint ventures or supply agreements to efficiently sell isotopes outside of Russia, according to MDS.
Isotope will provide MDS Nordion with a supplemental supply of Mo-99 until 2020, giving MDS a new source of the isotope for its customer base, which MDS hopes will offset the effects of the planned shutdown of Atomic Energy of Canada's National Research Universal reactor.
The initial quantities of Mo-99 supplied by Isotope to MDS will be incremental; over several years MDS expects the Russian company to supply up to 20% of global Mo-99 demand to back up MDS Nordion's long-term requirements. MDS expects to receive its first supply of Mo-99 from Isotope in the first half of fiscal 2011, the company said.
Related Reading
MDS advanced revenue in Q3, September 17, 2010
MDS extends cobalt-60 supply deal, August 13, 2010
Lantheus, MDS Nordion sign Mo-99 deal, July 8, 2010
MDS Nordion, Guerbet to develop PET agents, June 24, 2010
MDS posts Q2 loss, June 15, 2010
Copyright © 2010 AuntMinnie.com
